Evaluation of the Clinical Outcomes of Apixaban Use in Patients with Atrial Fibrillation and Uncontrolled Hypothyroidism: A Real-world Evidence

Introduction Atrial fibrillation (AF) poses a substantial worldwide health concern, significantly increasing the risk of stroke and morbidity. Direct oral anticoagulants (DOACs) such as apixaban are recommended over vitamin K antagonists for the management of AF. However, the impact of thyroid abnor...

全面介紹

書目詳細資料

發表在:	Clinical and Applied Thrombosis/Hemostasis
Main Authors:	Khalid Al Sulaiman BCCCP, BCNSP, MBA, FCCM, Manal A Aljohani PharmD, Abdullah F Alharthi PharmD, Hisham A Badreldin PharmD, Mohammed Y Alzahrani PharmD, Rahaf A Alqahtani PharmD, Walaa A Alshahrani PharmD, Fatimah M Abudayah PhD, Mohammad S Shawaqfeh PharmD, PhD, Ahmed A Alrashed PharmD, Alaa M Alenazi PharmD, Nouf S Alsagri PharmD, Mohammed Yahya Asiri PharmD, Zayed Asiri PharmD, Sulaiman Aljarallah PharmD, Yusuf M. Garwan PharmD, Lama S. Alfehaid PharmD, Abeer A. Alenazi PharmD, Tariq Aldebasi MD, Shmeylan Alharbi PharmD, Ahmed Aldemerdash PharmD, Amer Alzahrani MD, Ohoud Aljuhani PharmD
格式:	Article
語言:	英语
出版:	SAGE Publishing 2025-09-01
在線閱讀:	https://doi.org/10.1177/10760296251371043